A transdisciplinary model to inform randomized clinical trial methods for electronic cigarette evaluation

Alexa A. Lopez, Caroline O. Cobb, Jessica M. Yingst, Susan Veldheer, Shari Hrabovsky, Miao Shan Yen, Jonathan Foulds, Thomas Eissenberg

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: This study is a systematic evaluation of a novel tobacco product, electronic cigarettes (ECIGs) using a two-site, four-Arm, 6-month, parallel-group randomized controlled trial (RCT) with a follow-up to 9 months. Virginia Commonwealth University is the primary site and Penn State University is the secondary site. This RCT design is important because it is informed by analytical work, clinical laboratory results, and qualitative/quantitative findings regarding the specific ECIG products used. Methods: Participants (N = 520) will be randomized across sites and must be healthy smokers of >9 cigarettes for at least one year, who have not had a quit attempt in the prior month, are not planning to quit in the next 6 months, and are interested in reducing cigarette intake. Participants will be randomized into one of four 24-week conditions: A cigarette substitute that does not produce an inhalable aerosol; or one of three ECIG conditions that differ by nicotine concentration 0, 8, or 36 mg/ml. Blocked randomization will be accomplished with a 1:1:1:1 ratio of condition assignments at each site. Specific aims are to: characterize ECIG influence on toxicants, biomarkers, health indicators, and disease risk; determine tobacco abstinence symptom and adverse event profile associated with real-world ECIG use; and examine the influence of ECIG use on conventional tobacco product use. Liquid nicotine concentration-related differences on these study outcomes are predicted. Participants and research staff in contact with participants will be blinded to the nicotine concentration in the ECIG conditions. Discussion: Results from this study will inform knowledge concerning ECIG use as well as demonstrate a model that may be applied to other novel tobacco products. The model of using prior empirical testing of ECIG devices should be considered in other RCT evaluations. Trial registration: TRN: NCT02342795, registered December 16, 2014.

Original languageEnglish (US)
Article number217
JournalBMC Public Health
Volume16
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Randomized Controlled Trials
Tobacco Products
Nicotine
Electronic Cigarettes
Tobacco Use
Random Allocation
Aerosols
Tobacco
Biomarkers
Outcome Assessment (Health Care)
Equipment and Supplies
Health
Research

All Science Journal Classification (ASJC) codes

  • Public Health, Environmental and Occupational Health

Cite this

Lopez, Alexa A. ; Cobb, Caroline O. ; Yingst, Jessica M. ; Veldheer, Susan ; Hrabovsky, Shari ; Yen, Miao Shan ; Foulds, Jonathan ; Eissenberg, Thomas. / A transdisciplinary model to inform randomized clinical trial methods for electronic cigarette evaluation. In: BMC Public Health. 2016 ; Vol. 16, No. 1.
@article{6fc981bd23fb4e3cb10c0b6502d97549,
title = "A transdisciplinary model to inform randomized clinical trial methods for electronic cigarette evaluation",
abstract = "Background: This study is a systematic evaluation of a novel tobacco product, electronic cigarettes (ECIGs) using a two-site, four-Arm, 6-month, parallel-group randomized controlled trial (RCT) with a follow-up to 9 months. Virginia Commonwealth University is the primary site and Penn State University is the secondary site. This RCT design is important because it is informed by analytical work, clinical laboratory results, and qualitative/quantitative findings regarding the specific ECIG products used. Methods: Participants (N = 520) will be randomized across sites and must be healthy smokers of >9 cigarettes for at least one year, who have not had a quit attempt in the prior month, are not planning to quit in the next 6 months, and are interested in reducing cigarette intake. Participants will be randomized into one of four 24-week conditions: A cigarette substitute that does not produce an inhalable aerosol; or one of three ECIG conditions that differ by nicotine concentration 0, 8, or 36 mg/ml. Blocked randomization will be accomplished with a 1:1:1:1 ratio of condition assignments at each site. Specific aims are to: characterize ECIG influence on toxicants, biomarkers, health indicators, and disease risk; determine tobacco abstinence symptom and adverse event profile associated with real-world ECIG use; and examine the influence of ECIG use on conventional tobacco product use. Liquid nicotine concentration-related differences on these study outcomes are predicted. Participants and research staff in contact with participants will be blinded to the nicotine concentration in the ECIG conditions. Discussion: Results from this study will inform knowledge concerning ECIG use as well as demonstrate a model that may be applied to other novel tobacco products. The model of using prior empirical testing of ECIG devices should be considered in other RCT evaluations. Trial registration: TRN: NCT02342795, registered December 16, 2014.",
author = "Lopez, {Alexa A.} and Cobb, {Caroline O.} and Yingst, {Jessica M.} and Susan Veldheer and Shari Hrabovsky and Yen, {Miao Shan} and Jonathan Foulds and Thomas Eissenberg",
year = "2016",
month = "1",
day = "1",
doi = "10.1186/s12889-016-2792-8",
language = "English (US)",
volume = "16",
journal = "BMC Public Health",
issn = "1471-2458",
publisher = "BioMed Central",
number = "1",

}

A transdisciplinary model to inform randomized clinical trial methods for electronic cigarette evaluation. / Lopez, Alexa A.; Cobb, Caroline O.; Yingst, Jessica M.; Veldheer, Susan; Hrabovsky, Shari; Yen, Miao Shan; Foulds, Jonathan; Eissenberg, Thomas.

In: BMC Public Health, Vol. 16, No. 1, 217, 01.01.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A transdisciplinary model to inform randomized clinical trial methods for electronic cigarette evaluation

AU - Lopez, Alexa A.

AU - Cobb, Caroline O.

AU - Yingst, Jessica M.

AU - Veldheer, Susan

AU - Hrabovsky, Shari

AU - Yen, Miao Shan

AU - Foulds, Jonathan

AU - Eissenberg, Thomas

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Background: This study is a systematic evaluation of a novel tobacco product, electronic cigarettes (ECIGs) using a two-site, four-Arm, 6-month, parallel-group randomized controlled trial (RCT) with a follow-up to 9 months. Virginia Commonwealth University is the primary site and Penn State University is the secondary site. This RCT design is important because it is informed by analytical work, clinical laboratory results, and qualitative/quantitative findings regarding the specific ECIG products used. Methods: Participants (N = 520) will be randomized across sites and must be healthy smokers of >9 cigarettes for at least one year, who have not had a quit attempt in the prior month, are not planning to quit in the next 6 months, and are interested in reducing cigarette intake. Participants will be randomized into one of four 24-week conditions: A cigarette substitute that does not produce an inhalable aerosol; or one of three ECIG conditions that differ by nicotine concentration 0, 8, or 36 mg/ml. Blocked randomization will be accomplished with a 1:1:1:1 ratio of condition assignments at each site. Specific aims are to: characterize ECIG influence on toxicants, biomarkers, health indicators, and disease risk; determine tobacco abstinence symptom and adverse event profile associated with real-world ECIG use; and examine the influence of ECIG use on conventional tobacco product use. Liquid nicotine concentration-related differences on these study outcomes are predicted. Participants and research staff in contact with participants will be blinded to the nicotine concentration in the ECIG conditions. Discussion: Results from this study will inform knowledge concerning ECIG use as well as demonstrate a model that may be applied to other novel tobacco products. The model of using prior empirical testing of ECIG devices should be considered in other RCT evaluations. Trial registration: TRN: NCT02342795, registered December 16, 2014.

AB - Background: This study is a systematic evaluation of a novel tobacco product, electronic cigarettes (ECIGs) using a two-site, four-Arm, 6-month, parallel-group randomized controlled trial (RCT) with a follow-up to 9 months. Virginia Commonwealth University is the primary site and Penn State University is the secondary site. This RCT design is important because it is informed by analytical work, clinical laboratory results, and qualitative/quantitative findings regarding the specific ECIG products used. Methods: Participants (N = 520) will be randomized across sites and must be healthy smokers of >9 cigarettes for at least one year, who have not had a quit attempt in the prior month, are not planning to quit in the next 6 months, and are interested in reducing cigarette intake. Participants will be randomized into one of four 24-week conditions: A cigarette substitute that does not produce an inhalable aerosol; or one of three ECIG conditions that differ by nicotine concentration 0, 8, or 36 mg/ml. Blocked randomization will be accomplished with a 1:1:1:1 ratio of condition assignments at each site. Specific aims are to: characterize ECIG influence on toxicants, biomarkers, health indicators, and disease risk; determine tobacco abstinence symptom and adverse event profile associated with real-world ECIG use; and examine the influence of ECIG use on conventional tobacco product use. Liquid nicotine concentration-related differences on these study outcomes are predicted. Participants and research staff in contact with participants will be blinded to the nicotine concentration in the ECIG conditions. Discussion: Results from this study will inform knowledge concerning ECIG use as well as demonstrate a model that may be applied to other novel tobacco products. The model of using prior empirical testing of ECIG devices should be considered in other RCT evaluations. Trial registration: TRN: NCT02342795, registered December 16, 2014.

UR - http://www.scopus.com/inward/record.url?scp=85007441153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007441153&partnerID=8YFLogxK

U2 - 10.1186/s12889-016-2792-8

DO - 10.1186/s12889-016-2792-8

M3 - Article

C2 - 26941050

AN - SCOPUS:85007441153

VL - 16

JO - BMC Public Health

JF - BMC Public Health

SN - 1471-2458

IS - 1

M1 - 217

ER -